CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, vol.71, no.1, pp.27-38, 2019 (SCI-Expanded)
BACKGROUND: Selective Serotonin Reuptake Inhibitors (SSRIs), antidepressants commonly used in cardiovascular diseases (CVDs), inhibit the re-uptake of serotonin not only into neurons but also into platelets. Hence they increase the level of serotonin in plasma.